{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T17:09:02Z","timestamp":1754154542167,"version":"3.41.2"},"reference-count":32,"publisher":"Akademiai Kiado Zrt.","issue":"45","license":[{"start":{"date-parts":[[2023,11,12]],"date-time":"2023-11-12T00:00:00Z","timestamp":1699747200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2023,11,12]]},"abstract":"<jats:p><jats:italic>Bevezet\u00e9s:<\/jats:italic> Az akut myeloid leukaemia (AML) nagy mortalit\u00e1s\u00fa\n                    hematol\u00f3giai malignit\u00e1s, amelynek kezel\u00e9se k\u00fcl\u00f6n\u00f6sen a betegek t\u00f6bbs\u00e9g\u00e9t alkot\u00f3\n                    65 \u00e9v feletti korcsoportban nagy kih\u00edv\u00e1s. M\u00edg kor\u00e1bban az intenz\u00edv indukci\u00f3s\n                    ter\u00e1pi\u00e1ra nem alkalmas betegek sz\u00e1m\u00e1ra csup\u00e1n palliat\u00edv cytoreductio \u00e9s\n                    szupport\u00edv ell\u00e1t\u00e1s j\u00f6hetett sz\u00f3ba, 2018-t\u00f3l \u00faj kezel\u00e9si lehet\u0151s\u00e9gk\u00e9nt az\n                    azacitidin\u2013venetoklax-kombin\u00e1ci\u00f3 is megjelent. Klinikai vizsg\u00e1latokban ez a\n                    kezel\u00e9s jelent\u0151s t\u00fal\u00e9l\u00e9si el\u0151nnyel j\u00e1rt, arr\u00f3l azonban, hogy mennyire\n                    befoly\u00e1solta a mindennapi klinikai gyakorlatot \u00e9s a teljes betegpopul\u00e1ci\u00f3\n                    t\u00fal\u00e9l\u00e9s\u00e9t, kev\u00e9s adat \u00e1ll rendelkez\u00e9sre. <jats:italic>C\u00e9lkit\u0171z\u00e9s:<\/jats:italic> Azt\n                    szerett\u00fck volna megvizsg\u00e1lni, hogy az azacitidin\u2013venetoklax-kombin\u00e1ci\u00f3\n                    el\u00e9rhet\u0151s\u00e9ge hogyan v\u00e1ltoztatta meg az AML kezel\u00e9s\u00e9t \u00e9s a betegek t\u00fal\u00e9l\u00e9s\u00e9t\n                    klinik\u00e1nkon. <jats:italic>M\u00f3dszer:<\/jats:italic> Kutat\u00e1sunkban retrospekt\u00edven vizsg\u00e1ltuk\n                    minden, 2011. janu\u00e1r 1. \u00e9s 2021. december 31. k\u00f6z\u00f6tt a III. Sz. Belgy\u00f3gy\u00e1szati\n                    (2020 \u00f3ta Belgy\u00f3gy\u00e1szati \u00e9s Hematol\u00f3giai) Klinik\u00e1n AML-lel diagnosztiz\u00e1lt beteg\n                    t\u00fal\u00e9l\u00e9si adatait a kapott kezel\u00e9s \u00e9s a kezel\u00e9si id\u0151szak (2011\u20132017 vagy\n                    2018\u20132021) f\u00fcggv\u00e9ny\u00e9ben. A kutat\u00e1sb\u00f3l kiz\u00e1rtuk a promyelocyt\u00e1s leukaemi\u00e1val\n                    diagnosztiz\u00e1lt betegeket. <jats:italic>Eredm\u00e9nyek:<\/jats:italic> A vizsg\u00e1lt id\u0151szakban\n                    \u00f6sszesen 423 AML-beteget diagnosztiz\u00e1ltunk. Az esetsz\u00e1mok jelent\u0151sen n\u0151ttek: m\u00edg\n                    az els\u0151 7 \u00e9vben 184 beteget kezelt\u00fcnk, addig a m\u00e1sodik id\u0151szak csup\u00e1n 4 \u00e9ve\n                    alatt m\u00e1r 239-et. A betegek medi\u00e1n \u00e9letkora 67,6 \u00e9v, t\u00f6bb mint 60%-uk 65 \u00e9v\n                    feletti volt. A teljes v\u00e1rhat\u00f3 t\u00fal\u00e9l\u00e9s javul\u00f3 trendet mutatott: 2011 \u00e9s 2017\n                    k\u00f6z\u00f6tt 4,8 \u00b1 0,9 h\u00f3nap, m\u00edg 2018 \u00e9s 2021 k\u00f6z\u00f6tt 8,3 \u00b1 1,4 h\u00f3nap volt (p =\n                    0,051). Szignifik\u00e1nsan javult a teljes t\u00fal\u00e9l\u00e9s a 65 \u00e9v feletti betegek eset\u00e9n:\n                    3,1 \u00b1 0,5 \u00e9s 4,9 \u00b1 0,6 h\u00f3nap (p = 0,01). A javul\u00e1s h\u00e1tter\u00e9ben els\u0151sorban az\n                    \u00e1llhat, hogy a 65 \u00e9v feletti, kor\u00e1bban csak szupport\u00edvan kezelt betegek jelent\u0151s\n                    r\u00e9sz\u00e9t tudtuk akt\u00edvan kezelni azacitidin\u2013venetoklax-kombin\u00e1ci\u00f3val: az akt\u00edvan\n                    kezelt betegek ar\u00e1nya a m\u00e1sodik id\u0151szakban 57,1%-r\u00f3l 75,3%-ra n\u0151tt.\n                        <jats:italic>K\u00f6vetkeztet\u00e9s:<\/jats:italic> A 65 \u00e9v feletti, kurat\u00edv ter\u00e1pi\u00e1ra nem\n                    alkalmas betegek t\u00fal\u00e9l\u00e9se fokozatos javul\u00e1st mutatott, amihez val\u00f3sz\u00edn\u0171leg\n                    nagyban hozz\u00e1j\u00e1rult az \u00fajabb ter\u00e1pi\u00e1s alternat\u00edv\u00e1k klinikai gyakorlatban t\u00f6rt\u00e9n\u0151\n                    elterjed\u00e9se. Orv Hetil. 2023; 164(45): 1787\u20131794.<\/jats:p>","DOI":"10.1556\/650.2023.32901","type":"journal-article","created":{"date-parts":[[2023,11,12]],"date-time":"2023-11-12T08:50:47Z","timestamp":1699779047000},"page":"1787-1794","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":0,"title":["Hogyan v\u00e1ltozott az akut myeloid leukaemi\u00e1s betegek t\u00fal\u00e9l\u00e9se a ter\u00e1pi\u00e1s lehet\u0151s\u00e9gek b\u0151v\u00fcl\u00e9s\u00e9vel az elm\u00falt 10 \u00e9vben klinik\u00e1nkon?"],"prefix":"10.1556","volume":"164","author":[{"given":"Lilla","family":"Ga\u00e1l","sequence":"first","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar Budapest Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eszter","family":"Ruff","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar Budapest Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1d\u00e1m","family":"Wiedemann","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Hematol\u00f3giai Klinika Budapest, Szentkir\u00e1lyi u. 46., 1088 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Szabolcs","family":"Svorenj","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Hematol\u00f3giai Klinika Budapest, Szentkir\u00e1lyi u. 46., 1088 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vir\u00e1g R\u00e9ka","family":"Szita","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Hematol\u00f3giai Klinika Budapest, Szentkir\u00e1lyi u. 46., 1088 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e1s D\u00e1vid","family":"T\u00f3th","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Hematol\u00f3giai Klinika Budapest, Szentkir\u00e1lyi u. 46., 1088 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e1s","family":"Masszi","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Hematol\u00f3giai Klinika Budapest, Szentkir\u00e1lyi u. 46., 1088 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Horv\u00e1th","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Hematol\u00f3giai Klinika Budapest, Szentkir\u00e1lyi u. 46., 1088 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gergely","family":"Szombath","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Hematol\u00f3giai Klinika Budapest, Szentkir\u00e1lyi u. 46., 1088 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsolt","family":"Nagy","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Hematol\u00f3giai Klinika Budapest, Szentkir\u00e1lyi u. 46., 1088 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judit","family":"V\u00e1rkonyi","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Hematol\u00f3giai Klinika Budapest, Szentkir\u00e1lyi u. 46., 1088 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Szabolcs","family":"Benedek\u2020","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Hematol\u00f3giai Klinika Budapest, Szentkir\u00e1lyi u. 46., 1088 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e9ter","family":"Farkas","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Hematol\u00f3giai Klinika Budapest, Szentkir\u00e1lyi u. 46., 1088 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Csaba","family":"B\u00f6d\u00f6r","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Patol\u00f3giai \u00e9s K\u00eds\u00e9rleti R\u00e1kkutat\u00f3 Int\u00e9zet Budapest Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tam\u00e1s","family":"Masszi","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Hematol\u00f3giai Klinika Budapest, Szentkir\u00e1lyi u. 46., 1088 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gergely","family":"Varga","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Hematol\u00f3giai Klinika Budapest, Szentkir\u00e1lyi u. 46., 1088 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1080\/10428194.2017.1330956","article-title":"Acute myeloid leukemia in the elderly: therapeutic options and choice","volume":"59","author":"Webster JA","year":"2018","unstructured":"1 Webster JA, Pratz KW. Acute myeloid leukemia in the elderly: therapeutic options and choice. Leuk Lymphoma 2018; 59: 274-287.","journal-title":"Leuk Lymphoma"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41408-020-00376-1","article-title":"New directions for emerging therapies in acute myeloid leukemia: the next chapter","volume":"10","author":"2 Daver","year":"2020","unstructured":"2 Daver N, Wei AH, Pollyea DA, et al. New directions for emerging therapies in acute myeloid leukemia: the next chapter. Blood Cancer J. 2020; 10: 107.","journal-title":"Blood Cancer J"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3 Raska A, Krizs\u00e1n Sz, Nagy Zs, et al. Evaluation of acute myeloid leukemia patients treated between 2007 and 2017 at the 1st Department of Internal Medicine, Semmelweis University. [Akut myeloid leuk\u00e9mi\u00e1val 2007-2017 k\u00f6z\u00f6tt a Semmelweis Egyetem I. sz. Belgy\u00f3gy\u00e1szati Klinik\u00e1n kezelt betegek adatainak elemz\u00e9se.] Hematol Transzfuziol. 2019; 52: 215-224. [Hungarian]","DOI":"10.1556\/2068.2019.52.4.3"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"4 DiNardo","year":"2020","unstructured":"4 DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020; 383: 617-629.","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5 Telek B, Rejt\u0151 L, Bat\u00e1r P, et al. Drug treatment of acute myelogenous leukemia. Current options and future perspectives. [Az akut myeloid leukaemia gy\u00f3gyszeres kezel\u00e9se. Jelenlegi lehet\u0151s\u00e9gek, j\u00f6v\u0151beli kil\u00e1t\u00e1sok.] Orv Hetil. 2016; 157: 843-848. [Hungarian]","DOI":"10.1556\/650.2016.30433"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6 L\u00f6wenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009; 361: 1235-1248. Erratum: N Engl J Med. 2010; 362: 1155.","DOI":"10.1056\/NEJMoa0901409"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7 Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence - What is it and what can it tell us? N Engl J Med. 2016; 375: 2293-2297.","DOI":"10.1056\/NEJMsb1609216"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8 Weisinger J, T\u00e1rk\u00e1nyi I, Hanna E, et al. Retrospective analysis of chronic myeloid leukemia patients treated in the Department of Internal Medicine and Oncology, Semmelweis University, between 2003 and 2019. [Kr\u00f3nikus myeloid leukaemia miatt 2003 \u00e9s 2019 k\u00f6z\u00f6tt a Semmelweis Egyetem Belgy\u00f3gy\u00e1szati \u00e9s Onkol\u00f3giai Klinik\u00e1j\u00e1n kezelt betegek adatainak elemz\u00e9se.] Orv Hetil. 2021; 162: 1297-1302. [Hungarian]","DOI":"10.1556\/650.2021.32120"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"9 Arber","year":"2016","unstructured":"9 Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127: 2391-2405.","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"10 D\u00f6hner","year":"2017","unstructured":"10 D\u00f6hner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017; 129: 424-447.","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"10040","DOI":"10.3390\/ijms221810040","article-title":"Significance of NPM1 gene mutations in AML","volume":"22","author":"11 Hindley","year":"2021","unstructured":"11 Hindley A, Catherwood MA, McMullin MF, et al. Significance of NPM1 gene mutations in AML. Int J Mol Sci. 2021; 22: 10040.","journal-title":"Int J Mol Sci"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"5565","DOI":"10.1182\/bloodadvances.2021005538","article-title":"Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia","volume":"5","author":"12 Cherry","year":"2021","unstructured":"12 Cherry EM, Abbott D, Amaya M, et al. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Blood Adv. 2021; 5: 5565-5573.","journal-title":"Blood Adv"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13 Begna KH, Gangat N, Al-Kali A, et al. Acute myeloid leukemia after age 70 years: a retrospective comparison of survival following treatment with intensive versus HMA \u00b1 venetoclax chemotherapy. Am J Hematol. 2021; 96: E108-E111.","DOI":"10.1002\/ajh.26112"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"20406207211040335","DOI":"10.1177\/20406207211040335","article-title":"Venetoclax combination therapy with hypomethylating agents in young adults with relapsed\/refractory acute myeloid leukaemia","volume":"12","author":"14 B\u00e1ez-Guti\u00e9rrez","year":"2021","unstructured":"14 B\u00e1ez-Guti\u00e9rrez N, Rodr\u00edguez-Ramallo H, Moreno MA, et al. Venetoclax combination therapy with hypomethylating agents in young adults with relapsed\/refractory acute myeloid leukaemia. Ther Adv Hematol. 2021; 12: 20406207211040335.","journal-title":"Ther Adv Hematol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/ajh.26039","article-title":"Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow-up from a phase 1b study","volume":"96","author":"15 Pollyea","year":"2021","unstructured":"15 Pollyea DA, Pratz K, Letai A, et al. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow-up from a phase 1b study. Am J Hematol. 2021; 96: 208-217.","journal-title":"Am J Hematol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.3390\/cancers15082399","article-title":"Optimizing treatment options for newly diagnosed acute myeloid leukemia in older patients with comorbidities","volume":"15","author":"Oshikawa G","year":"2023","unstructured":"16 Oshikawa G, Sasaki K. Optimizing treatment options for newly diagnosed acute myeloid leukemia in older patients with comorbidities. Cancers (Basel) 2023; 15: 2399.","journal-title":"Cancers (Basel)"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"6794","DOI":"10.3390\/curroncol29100535","article-title":"Real-world treatment patterns and clinical outcomes in Canadian patients with AML unfit for first-line intensive chemotherapy","volume":"29","author":"17 Sanford","year":"2022","unstructured":"17 Sanford D, Desjardins P, Leber B, et al. Real-world treatment patterns and clinical outcomes in Canadian patients with AML unfit for first-line intensive chemotherapy. Curr Oncol. 2022; 29: 6794-6806.","journal-title":"Curr Oncol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1002\/cncr.30704","article-title":"Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach","volume":"123","author":"18 Boddu","year":"2017","unstructured":"18 Boddu PC, Kantarjian HM, Ravandi F, et al. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach. Cancer 2017; 123: 3050-3060.","journal-title":"Cancer"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"19 Dombret","year":"2015","unstructured":"19 Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood 2015; 126: 291-299.","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20 Kadia TM, Wei AH. Evolution of therapy for older patients with acute myeloid leukemia: how should we use currently available agents? Cancer J. 2022; 28: 67-72.","DOI":"10.1097\/PPO.0000000000000574"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"79126","DOI":"10.18632\/oncotarget.15988","article-title":"Azacitidine or intensive chemotherapy for older patients with secondary or therapy-related acute myeloid leukemia","volume":"8","author":"21 Dumas","year":"2017","unstructured":"21 Dumas PY, Bertoli S, B\u00e9rard E, et al. Azacitidine or intensive chemotherapy for older patients with secondary or therapy-related acute myeloid leukemia. Oncotarget 2017; 8: 79126-79136.","journal-title":"Oncotarget"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia","volume":"386","author":"22 Montesinos","year":"2022","unstructured":"22 Montesinos P, Recher C, Vives S, et al. Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. N Engl J Med. 2022; 386: 1519-1531.","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"23 D\u00f6hner","year":"2022","unstructured":"23 D\u00f6hner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 2022; 140: 1345-1377.","journal-title":"Blood"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24 Szak\u00e1cs Z, Alizadeh H. New perspectives in treating acute myeloid leukemia: driving towards a patient-tailored strategy. [Az akut mieloid leuk\u00e9mia kezel\u00e9s\u00e9nek \u00faj lehet\u0151s\u00e9gei: \u00fat a szem\u00e9lyre szabott ter\u00e1pi\u00e1s strat\u00e9gi\u00e1k fel\u00e9.] Hematol Transzfuziol. 2022; 55: 95-114. [Hungarian]","DOI":"10.1556\/2068.2022.00151"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25 L\u00e9vesque LE, Hanley JA, Kezouh A, et al. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ 2010; 340: b5087.","DOI":"10.1136\/bmj.b5087"},{"key":"ref25","unstructured":"26 Gopcsa L, Alizadeh H, Andrikovics H, et al. Results of allogenic stem cell transplantation followed by primary venetoclax-azacitidin (VEN-AZA) induction treatment in acute myeloid leukemia. [AML-ben primer venetoclax-azacitidin (VEN-AZA) indukci\u00f3s kezel\u00e9st k\u00f6vet\u0151en v\u00e9gzett allog\u00e9n \u0151ssejt-transzplant\u00e1ci\u00f3k eredm\u00e9nyei. El\u0151ad\u00e1skivonat. Magyar Hematol\u00f3giai \u00e9s Transzfuziol\u00f3giai T\u00e1rsas\u00e1g XXIX. Kongresszusa, Esztergom, 2023. m\u00e1jus 25-27.] Hematol Transzfuziol. 2023; 56(Suppl 1): 1-65. [Hungarian]"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/ajh.26061","article-title":"Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: a propensity score matched analysis stratified by risk of treatment-related mortality","volume":"96","author":"27 Maiti","year":"2021","unstructured":"27 Maiti A, Qiao W, Sasaki K, et al. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: a propensity score matched analysis stratified by risk of treatment-related mortality. Am J Hematol. 2021; 96: 282-291.","journal-title":"Am J Hematol"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"28 Tofthagen C. Threats to validity in retrospective studies. J Adv Pract Oncol. 2012; 3: 181-183.","DOI":"10.6004\/jadpro.2012.3.3.7"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.bjhh.2015.03.007","article-title":"Limitations of performance status assessment in elderly with acute myeloid leukemia","volume":"37","author":"Carbonell AL","year":"2015","unstructured":"29 Carbonell AL, de Lourdes Chauffaille M. Limitations of performance status assessment in elderly with acute myeloid leukemia. Rev Bras Hematol Hemoter. 2015; 37: 259-262.","journal-title":"Rev Bras Hematol Hemoter"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"30 Darag\u00f3 A, Schwegler G, Szab\u00f3 E, et al. Early postoperative effects of kidney transplantation on the cardiovascular system in our clinical practice. [A vesetranszplant\u00e1ci\u00f3 korai posztoperat\u00edv hat\u00e1sai a sz\u00edv- \u00e9s \u00e9rrendszeri betegs\u00e9gekre klinikai gyakorlatunkban.] Orv Hetil. 2021; 162: 1052-1062. [Hungarian]","DOI":"10.1556\/650.2021.32269"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/cpt.2272","article-title":"Understanding use of real-world data and real-world evidence to support regulatory decisions on medical product effectiveness","volume":"111","author":"31 Mahendraratnam","year":"2022","unstructured":"31 Mahendraratnam N, Mercon K, Gill M, et al. Understanding use of real-world data and real-world evidence to support regulatory decisions on medical product effectiveness. Clin Pharmacol Ther. 2022; 111: 150-154.","journal-title":"Clin Pharmacol Ther"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"32 Bartlett VL, Dhruva SS, Shah ND, et al. Feasibility of using real-world data to replicate clinical trial evidence. JAMA Netw Open 2019; 2: e1912869.","DOI":"10.1001\/jamanetworkopen.2019.12869"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/164\/45\/article-p1787.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/164\/45\/article-p1787.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/164\/45\/article-p1787.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T13:13:43Z","timestamp":1753362823000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/164\/45\/article-p1787.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,12]]},"references-count":32,"journal-issue":{"issue":"45"},"URL":"https:\/\/doi.org\/10.1556\/650.2023.32901","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"type":"print","value":"0030-6002"},{"type":"electronic","value":"1788-6120"}],"subject":[],"published":{"date-parts":[[2023,11,12]]}}}